2025
SJR Q3
JCR Q3 · 2,7
25 matched articles
SCIE
Journal detail
Journal of Antibiotics
- Publisher
- Springer Nature
- Country
- United Kingdom · Western Europe
- Type
- journal
- ISSN
-
0021882018811469
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,414
- Quartile Q3
- H-Index 99
- Cites/doc 2,46
- Docs (3y) 279
- Cites (3y) 676
Clarivate
Web of Science · JCR · 2025
- JCR Q Q3
- JIF 2,7
- 5Y JIF 2,8
- JCI 0,57
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Drug Discovery Q3
- Pharmacology Q3
Areas
- Pharmacology, Toxicology and Pharmaceutics
WoS categories
- Biotechnology & Applied Microbiology | Immunology | Microbiology | Pharmacology & Pharmacy
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q3 | Q3 | 0,414 | 2,7 | 2,8 | 0,57 | Q3 | 99 |
| 2024 | Q3 | Q2 | 0,481 | 2,7 | 2,7 | 0,6 | Q3 | 96 |
| 2023 | Q3 | Q3 | 0,546 | 2,1 | 2,5 | 0,57 | Q3 | 96 |
| 2022 | Q2 | Q2 | 0,514 | 3,3 | 3 | 0,59 | Q3 | 96 |
| 2021 | Q3 | Q2 | 0,514 | 3,4 | 3,1 | 0,61 | Q3 | 96 |
| 2020 | Q3 | Q3 | 0,56 | 2,6 | 2,8 | 0,65 | Q3 | 96 |
| 2019 | Q2 | Q2 | 0,559 | 2,7 | 2,3 | 0,65 | Q3 | 96 |
| 2018 | — | Q3 | — | 2,4 | 2,3 | 0,71 | Q2 | — |
| 2017 | Q2 | Q3 | 0,762 | 2 | 2,3 | 0,65 | Q3 | 96 |
| 2016 | Q2 | Q2 | 0,733 | 2,2 | 2,1 | — | — | 96 |
| 2015 | Q2 | Q2 | 0,75 | 2,2 | 2 | — | — | 96 |
| 2014 | Q2 | Q3 | 0,649 | 1,7 | 1,8 | — | — | 96 |
| 2013 | Q2 | Q3 | 0,712 | 2 | 1,9 | — | — | 96 |
| 2012 | Q2 | Q2 | 0,877 | 2,2 | 1,9 | — | — | 96 |
| 2011 | Q2 | Q3 | 0,648 | 1,7 | 1,6 | — | — | 96 |
| 2010 | Q2 | Q3 | 0,619 | 1,6 | 1,6 | — | — | 96 |
| 2009 | — | Q3 | — | 1,6 | 1,8 | — | — | — |
| 2008 | — | Q3 | — | 1,3 | 1,4 | — | — | — |
| 2007 | — | Q3 | — | 1,3 | 1,4 | — | — | — |
| 2006 | — | Q3 | — | 1,3 | — | — | — | — |
| 2005 | — | Q3 | — | 1,5 | — | — | — | — |
| 2004 | — | Q2 | — | 1,4 | — | — | — | — |
| 2003 | — | Q2 | — | 1,2 | — | — | — | — |
| 2002 | — | Q2 | — | 1,4 | — | — | — | — |
| 2001 | — | Q2 | — | 1,3 | — | — | — | — |
| 2000 | — | Q2 | — | 1,3 | — | — | — | — |
| 1999 | — | Q2 | — | 1,1 | — | — | — | — |
| 1998 | — | Q2 | — | 1,1 | — | — | — | — |
| 1997 | — | Q2 | — | 1,5 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q3 | Q3 | 112/180 |
| 2025 | IMMUNOLOGY | SCIE | Q3 | Q3 | 124/183 |
| 2025 | MICROBIOLOGY | SCIE | Q3 | Q3 | 110/167 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 191/356 |
| 2024 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q3 | Q3 | 96/177 |
| 2024 | IMMUNOLOGY | SCIE | Q3 | Q3 | 112/183 |
| 2024 | MICROBIOLOGY | SCIE | Q3 | Q3 | 90/163 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 164/352 |
| 2023 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q3 | Q3 | 123/174 |
| 2023 | IMMUNOLOGY | SCIE | Q4 | Q3 | 141/181 |
| 2023 | MICROBIOLOGY | SCIE | Q3 | Q3 | 117/161 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 210/354 |
| 2022 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q2 | Q3 | 76/158 |
| 2022 | IMMUNOLOGY | SCIE | Q3 | Q3 | 106/161 |
| 2022 | MICROBIOLOGY | SCIE | Q3 | Q3 | 71/135 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 138/278 |
| 2021 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q2 | Q3 | 78/159 |
| 2021 | IMMUNOLOGY | SCIE | Q3 | Q3 | 117/162 |
| 2021 | MICROBIOLOGY | SCIE | Q3 | Q3 | 82/137 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 150/279 |
| 2020 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q3 | Q3 | 104/159 |
| 2020 | IMMUNOLOGY | SCIE | Q4 | Q3 | 129/162 |
| 2020 | MICROBIOLOGY | SCIE | Q3 | Q3 | 98/136 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 186/276 |
| 2019 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q2 | Q3 | 75/156 |
| 2019 | IMMUNOLOGY | SCIE | Q3 | Q3 | 107/159 |
| 2019 | MICROBIOLOGY | SCIE | Q3 | Q3 | 80/136 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 140/271 |
| 2018 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q3 | Q2 | 82/162 |
| 2018 | IMMUNOLOGY | SCIE | Q3 | Q3 | 116/158 |
| 2018 | MICROBIOLOGY | SCIE | Q3 | Q2 | 85/133 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 144/267 |
| 2017 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q3 | Q3 | 88/161 |
| 2017 | IMMUNOLOGY | SCIE | Q4 | Q3 | 123/155 |
| 2017 | MICROBIOLOGY | SCIE | Q3 | Q3 | 83/126 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 169/261 |
| 2016 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q2 | — | 76/160 |
| 2016 | IMMUNOLOGY | SCIE | Q3 | — | 110/151 |
| 2016 | MICROBIOLOGY | SCIE | Q3 | — | 71/125 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 145/257 |
| 2015 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q2 | — | 75/161 |
| 2015 | IMMUNOLOGY | SCIE | Q3 | — | 106/151 |
| 2015 | MICROBIOLOGY | SCIE | Q3 | — | 75/123 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 139/255 |
| 2014 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q3 | — | 98/163 |
| 2014 | IMMUNOLOGY | SCIE | Q4 | — | 124/148 |
| 2014 | MICROBIOLOGY | SCIE | Q3 | — | 88/119 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 166/255 |
| 2013 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q3 | — | 84/165 |
| 2013 | IMMUNOLOGY | SCIE | Q4 | — | 109/144 |
| 2013 | MICROBIOLOGY | SCIE | Q3 | — | 75/119 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 147/256 |
| 2012 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q2 | — | 75/160 |
| 2012 | IMMUNOLOGY | SCIE | Q3 | — | 99/137 |
| 2012 | MICROBIOLOGY | SCIE | Q3 | — | 65/116 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 131/261 |
| 2011 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q3 | — | 98/158 |
| 2011 | IMMUNOLOGY | SCIE | Q4 | — | 116/139 |
| 2011 | MICROBIOLOGY | SCIE | Q3 | — | 77/114 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 171/261 |
| 2010 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q3 | — | 97/160 |
| 2010 | IMMUNOLOGY | SCIE | Q4 | — | 108/134 |
| 2010 | MICROBIOLOGY | SCIE | Q3 | — | 74/107 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 168/252 |
| 2009 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q3 | — | 91/152 |
| 2009 | IMMUNOLOGY | SCIE | Q4 | — | 104/128 |
| 2009 | MICROBIOLOGY | SCIE | Q4 | — | 73/95 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 159/237 |
| 2008 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q3 | — | 100/144 |
| 2008 | IMMUNOLOGY | SCIE | Q4 | — | 105/121 |
| 2008 | MICROBIOLOGY | SCIE | Q4 | — | 74/91 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 166/219 |
| 2007 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q3 | — | 92/138 |
| 2007 | IMMUNOLOGY | SCIE | Q4 | — | 100/119 |
| 2007 | MICROBIOLOGY | SCIE | Q3 | — | 69/93 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 146/205 |
| 2006 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q3 | — | 90/140 |
| 2006 | IMMUNOLOGY | SCIE | Q4 | — | 99/117 |
| 2006 | MICROBIOLOGY | SCIE | Q4 | — | 72/89 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 141/199 |
| 2005 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q3 | — | 76/139 |
| 2005 | IMMUNOLOGY | SCIE | Q4 | — | 87/115 |
| 2005 | MICROBIOLOGY | SCIE | Q3 | — | 61/86 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 118/193 |
| 2004 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q2 | — | 63/133 |
| 2004 | IMMUNOLOGY | SCIE | Q4 | — | 86/111 |
| 2004 | MICROBIOLOGY | SCIE | Q3 | — | 60/84 |
| 2004 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 115/187 |
| 2003 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q2 | — | 65/132 |
| 2003 | IMMUNOLOGY | SCIE | Q3 | — | 84/114 |
| 2003 | MICROBIOLOGY | SCIE | Q3 | — | 55/84 |
| 2003 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 122/185 |
| 2002 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q2 | — | 53/131 |
| 2002 | IMMUNOLOGY | SCIE | Q3 | — | 84/119 |
| 2002 | MICROBIOLOGY | SCIE | Q3 | — | 49/82 |
| 2002 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 102/188 |
| 2001 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q2 | — | 56/131 |
| 2001 | IMMUNOLOGY | SCIE | Q3 | — | 80/114 |
| 2001 | MICROBIOLOGY | SCIE | Q3 | — | 51/81 |
| 2001 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 104/186 |
| 2000 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q2 | — | 51/134 |
| 2000 | IMMUNOLOGY | SCIE | Q3 | — | 78/116 |
| 2000 | MICROBIOLOGY | SCIE | Q3 | — | 45/83 |
| 2000 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 86/181 |
| 1999 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q2 | — | 52/124 |
| 1999 | IMMUNOLOGY | SCIE | Q3 | — | 82/115 |
| 1999 | MICROBIOLOGY | SCIE | Q3 | — | 49/79 |
| 1999 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 94/175 |
| 1998 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q2 | — | 52/123 |
| 1998 | IMMUNOLOGY | SCIE | Q3 | — | 83/120 |
| 1998 | MICROBIOLOGY | SCIE | Q3 | — | 44/81 |
| 1998 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 92/178 |
| 1997 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q2 | — | 34/94 |
| 1997 | IMMUNOLOGY | SCIE | Q3 | — | 61/117 |
| 1997 | MICROBIOLOGY | SCIE | Q2 | — | 30/73 |
| 1997 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 58/157 |